For UK MedTech companies
Your clinical evidence is strong. UK payers are still saying no.
NHS commissioners and private insurers fund on health economics, not clinical outcomes alone. Without a UK-specific value case, even well-evidenced medtech stalls at the reimbursement stage indefinitely.
Two minutes. Solva follows up with specific health economics and market access options.
- Delayed or failed market access for innovative MedTech products in the UK
- Products with strong clinical benefits struggling to gain adoption due to lack of economic justification
- Increased internal resource strain as companies attempt to retrospectively generate health economic evidence
- Loss of competitive advantage to companies that effectively demonstrate value to UK payers
- Diversion of R&D resources to address market access hurdles rather than new product development
- Increased workload for commercial and regulatory teams attempting to navigate complex reimbursement pathways
- Significant loss of potential revenue from the NHS and private healthcare markets
- Reduced return on investment for product development and clinical trials
- Damage to company reputation as an innovator if products fail to reach patients
- Reduced attractiveness to investors due to market access challenges
No verified UK data available
Source: Search conducted on NICE and UK health economics literature (June 2026)
Frequently asked questions
Why does this problem persist?
UK payers - NHS commissioners and private insurers - make reimbursement decisions based on health economics evidence, not clinical evidence alone. Most MedTech companies don't have a UK-specific health economics case.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.